Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study

By D. Haas, H. Ribaudo, R. Kim, C. Tierney, G. Wilkinson, R. Gulick, D. Clifford, T. Hulgan, Catia Marzolini, E. Acosta. AIDS (London), 2004

703 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Polymorphism of human cytochrome P450 enzymes and its clinical impact (2009, background): “The efavirenz levels in African-American subjects with the CYP2B6 homozygous 516T/T genotype were ∼3-fold higher than individuals carrying the homozygous G/G genotype (Haas et al., 2004).”
Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. (2013, background): “The 15631T [Q172H] variant was furthermore associated with increased neurotoxicity and other CNS side effects (Haas et al., 2004; King & Aberg, 2008; Lubomirov et al., 2010; Ribaudo et al., 2010; Maimbo et al., 2011) with highly active antiretroviral therapy (HAART)-induced liver injury (Yimer et…”